First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - Chapter 5: Recipient monitoring and response plan for preventing disease transmission

Xenotransplantation

Volumn 23, Issue 1, 2016, Pages 53-59

  Denner, Joachim ^a   Tönjes, Ralf R ^b   Takeuchi, Yasu ^c   Fishman, Jay ^d   Scobie, Linda ^e  

^a ROBERT KOCH INSTITUTE   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

Author keywords

CRISPR Cas; designated pathogen free status; disease transmission; hepatitis E virus; infectious disease; islet xenotransplantation; porcine endogenous retrovirus; type 1 diabetes; xenozoonoses

Indexed keywords

ALGINIC ACID;

ALLOTRANSPLANTATION; ARTICLE; BACTERIAL TRANSMISSION; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DISEASE TRANSMISSION; ENDOGENOUS RETROVIRUS; GERMFREE ANIMAL; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL SOCIETY; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PARASITE TRANSMISSION; PATIENT SAFETY; PIG; PRIORITY JOURNAL; RISK REDUCTION; VIRUS DETECTION; VIRUS TRANSMISSION; XENOTRANSPLANTATION; ADVERSE EFFECTS; ANIMAL; DIABETES MELLITUS, TYPE 1; ISOLATION AND PURIFICATION; PREVENTION AND CONTROL; XENOGRAFT;

ANIMALS; DIABETES MELLITUS, TYPE 1; DISEASE TRANSMISSION, INFECTIOUS; ENDOGENOUS RETROVIRUSES; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84960802037     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12227     Document Type: Article

References (89)

1. Denner J, Tönjes RR,. Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses. Clin Microbiol Rev 2012; 25: 318-343.
2. Denner J,. Porcine endogenous retrovirus infection of human peripheral blood mononuclear cells. Xenotransplantation 2015; 22: 151-152.
3. Denner J, Schuurman HJ, Patience C,. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 5: Strategies to prevent transmission of porcine endogenous retroviruses. Xenotransplantation 2009; 16: 239-248.
4. Busby SA, Crossan C, Godwin J, et al., Suggestions for the diagnosis and elimination of hepatitis E virus in pigs used for xenotransplantation. Xenotransplantation 2013; 20: 188-192.
5. Mueller NJ, Takeuchi Y, Mattiuzzo G, et al., Microbial safety in xenotransplantation. Curr Opin Organ Transplant 2011; 16: 201-206.
6. Denner J,. Xenotransplantation and Hepatitis E virus. Xenotransplantation 2015; 22: 167-173.
7. Denner J,. Xenotransplantation and porcine cytomegalovirus (PCMV). Xenotransplantation 2015; 22: 329-335.
8. Morozov VA, Morozov AV, Rotem A, et al., Extended microbiological characterization of Göttingen Minipigs in the context of xenotransplantation: Detection and vertical transmission of Hepatitis E virus. PLoS ONE 2015; 10: E0139893.
9. Morozov VA, Morozov AV, Denner J,. New PCR diagnostic systems for the detection and quantification of the porcine cytomegalovirus (PCMV). Arch Virol 2016; [Epub ahead of print].
10. Tuch BE, Keogh GW, Williams LJ, et al., Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care 2009; 32: 1887-1889.
11. Paradis K, Langford G, Long Z, et al., Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 1999 Aug 20; 285: 1236-1241.
12. Elliott RB, Escobar L, Garkavenko O, et al., No evidence of infection with porcine endogenous retrovirus in recipients of encapsulated porcine islet xenografts. Cell Transplant 2000; 9: 895-901.
13. Garkavenko O, Croxson MC, Irgang M, et al., Monitoring for presence of potentially xenotic viruses in recipients of pig islet xenotransplantation. J Clin Microbiol 2004; 42: 5353-5356.
14. Valdés-González RA, Dorantes LM, Garibay GN, et al., Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: A 4-year study. Eur J Endocrinol 2005; 153: 419-427.
15. Elliott RB, Escobar L, Tan PL, et al., Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation 2007; 14: 157-161.
16. Wynyard S, Nathu D, Garkavenko O, et al., Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand. Xenotransplantation 2014; 21: 309-323.
17. Scobie L, Padler-Karavan IV, Le Bas-Bernardet S, et al., Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts. J Immunol 2013; 191: 2907-2915.
18. Bouwknegt M, Lodder-Verschoor F, Van Der Poel WH, et al., Hepatitis E virus RNA in commercial porcine livers in The Netherlands. J Food Prot 2007; 70: 2889-2895.
19. Colson P, Borentain P, Queyriaux B, et al., Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis 2010; 202: 825-834.
20. De Deus N, Casas M, Peralta B, et al., Hepatitis E virus infection dynamics and organic distribution in naturally infected pigs in a farrow-to-finish farm. Vet Microbiol 2008; 132: 19-28.
21. De Deus N, Seminati C, Pina S, et al., Detection of hepatitis E virus in liver, mesenteric lymph node, serum, bile and faeces of naturally infected pigs affected by different pathological conditions. Vet Microbiol 2007; 119: 105-114.
22. Tanaka H, Yoshino H, Kobayashi E, et al., Molecular investigation of hepatitis E virus infection in domestic and miniature pigs used for medical experiments. Xenotransplantation 2004; 11: 503-510.
23. Yazaki Y, Mizuo H, Takahashi M, et al., Sporadic acute or fulminant hepatitis E in Hokkaido, Japan, may be food-borne, as suggested by the presence of hepatitis E virus in pig liver as food. J Gen Virol 2003; 84: 2351-2357.
24. Scobie L, Dalton HR,. Hepatitis E: Source and route of infection, clinical manifestations and new developments. J Viral Hepat 2013; 20: 1-11.
25. Meng XJ,. Zoonotic and foodborne transmission of hepatitis E virus. Semin Liver Dis 2013; 33: 41-49.
26. Colson P, Kaba M, Moreau J, et al., Hepatitis E in an HIV-infected patient. J Clin Virol 2009; 45: 269-271.
27. Dalton HR, Bendall RP, Keane FE, et al., Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009; 361: 1025-1027.
28. Gerolami R, Moal V, Colson P,. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med 2008; 358: 859-860.
29. Gerolami R, Moal V, Picard C, et al., Hepatitis E virus as an emerging cause of chronic liver disease in organ transplant recipients. J Hepatol 2009; 50: 622-624.
30. Hamid SS, Jafri SM, Khan H, et al., Fulminant hepatic failure in pregnant women: Acute fatty liver or acute viral hepatitis? J Hepatol 1996; 25: 20-27.
31. Meng XJ,. Recent advances in Hepatitis E virus. J Viral Hepat 2010; 17: 153-161.
32. Labrique AB, Sikder SS, Krain LJ, et al., Hepatitis E, A vaccine-preventable cause of maternal deaths. Emerg Infect Dis 2012; 18: 1401-1404.
33. Kamar N, Abravanel F, Lhomme S, et al., Hepatitis E virus: Chronic infection, extra-hepatic manifestations, and treatment. Clin Res Hepatol Gastroenterol 2015; 39: 20-27.
34. Kamar N, Izopet J, Tripon S, et al., Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014; 370: 1111-1120.
35. Martin U, Winkler ME, Id M, et al., Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV). Xenotransplantation 2000; 7: 138-142.
36. Blusch JH, Patience C, Takeuchi Y, et al., Infection of nonhuman primate cells by pig endogenous retrovirus. J Virol 2000; 74: 7687-7690.
37. Specke V, Tacke SJ, Boller K, et al., Porcine endogenous retroviruses: In vitro host range and attempts to establish small animal models. J Gen Virol 2001; 82: 837-844.
38. Ritzhaupt A, VanDerLaan LJ, Salomon DR, et al., Porcine endogenous retrovirus infects but does not replicate in nonhuman primate primary cells and cell lines. J Virol 2002; 76: 11312-11320.
39. Garkavenko O, Dieckhof B, Wynyard S, et al., Absence of transmission of potentially xenotic viruses in a prospective pig to primate islet xenotransplantation study. J Med Virol 2008; 80: 2046-2052.
40. Moscoso I, Hermida-Prieto M, Mañez R,. et al. Lack of cross-species transmission of porcine endogenous retrovirus in pig-to-baboon xenotransplantation with sustained depletion of anti-alphagal antibodies. Transplantation 2005; 79: 777-782.
41. Nishitai R, Ikai I, Shiotani T, et al., Absence of PERV infection in baboons after transgenic porcine liver perfusion. J Surg Res 2005; 124: 45-51.
42. Martin U, Tacke SJ, Simon AR, et al., Absence of PERV specific humoral immune response in baboons after transplantation of porcine cells or organs. Transpl Int 2002; 15: 361-368.
43. Specke V, Plesker R, Wood J, et al., No in vivo infection of triple immunosuppressed non-human primates after inoculation with high titers of porcine endogenous retroviruses. Xenotransplantation 2009; 16: 34-44.
44. Mattiuzzo G, Takeuchi Y,. Suboptimal porcine endogenous retrovirus infection in non-human primate cells: Implication for preclinical xenotransplantation. PLoS ONE 2010; 5: E13203.
45. Denner J, Graham M,. Xenotransplantation of islet cells: What can the non-human primate model bring for the evaluation of efficacy and safety? Xenotransplantation 2015; 22: 231-235.
46. Groenen MA, Archibald AL, Uenishi H, et al., Analyses of pig genomes provide insight into porcine demography and evolution. Nature 2012; 491: 393-398.
47. Jiang J, Wang J, Wang H, et al., Global copy number analyses by next generation sequencing provide insight into pig genome variation. BMC Genom 2014; 15: 593.
48. Niebert M, Tönjes RR,. Analyses of prevalence and polymorphisms of six replication-competent and chromosomally assigned porcine endogenous retroviruses in individual pigs and pig subspecies. Virology 2003; 313: 427-434.
49. Niebert M, Tönjes RR,. Evolutionary spread and recombination of porcine endogenous retroviruses in the suiformes. J Virol 2005; 79: 649-654.
50. Dieckhoff B, Kessler B, Jobst D, et al., Distribution and expression of porcine endogenous retroviruses in multi-transgenic pigs generated for xenotransplantation. Xenotransplantation 2009; 16: 64-73.
51. Denner J,. Recombinant porcine endogenous retroviruses (PERV-A/C): A new risk for xenotransplantation? Arch Virol 2008; 153: 1421-1426.
52. Goff SP,. Retrovirus restriction factors. Mol Cell 2004; 16: 849-859.
53. Meije Y, Tönjes RR, Fishman JA,. Retroviral restriction factors and infectious risk in xenotransplantation. Amer J Transplant 2010; 10: 1511-1516.
54. Wood A, Webb BL, Bartosch B, et al., Porcine endogenous retroviruses PERV A and A/C recombinant are insensitive to a range of divergent mammalian TRIM5alpha proteins including human TRIM5alpha. J Gen Virol 2009; 90: 702-709.
55. Mattiuzzo G, Ivol S, Takeuchi Y,. Regulation of porcine endogenous retrovirus release by porcine and human tetherins. J Virol 2010; 84: 2618-2622.
56. Dörrschuck E, Fischer N, Bravo IG, et al., Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases. J Virol 2011; 85: 3842-3857.
57. Lee J, Choi JY, Lee HJ, et al., Repression of porcine endogenous retrovirus infection by human APOBEC3 proteins. Biochem Biophys Res Commun 2011; 407: 266-270.
58. Dörrschuck E, Münk C, Tönjes RR,. APOBEC3 proteins and porcine endogenous retroviruses. Transplant Proc 2008; 40: 959-961.
59. Wilhelm M, Fishman JA, Pontikis R, et al., Susceptibility of recombinant porcine endogenous retrovirus reverse transcriptase to nucleoside and non-nucleoside inhibitors. Cell Mol Life Sci 2002; 59: 2184-2190.
60. Stephan O, Schwendemann J, Specke V, et al., Porcine endogenous retroviruses (PERVs): Generation of specific antibodies, development of an immunoperoxidase assay (IPA) and inhibition by AZT. Xenotransplantation 2001; 8: 310-316.
61. Qari SH, Magre S, García-Lerma JG, et al., Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitor. J Virol 2001; 75: 1048-1053.
62. Powell SK, Gates ME, Langford G, et al., Antiretroviral agents inhibit infection of human cells by porcine endogenous retroviruses. Antimicrob Agents Chemother 2000; 44: 3432-3433.
63. Yang L, Güell M, Niu D, et al., Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science 2015; 350: 1101-1104.
64. Denner J,. Elimination of porcine endogenous retroviruses from pig cells. Xenotransplantation 2015; 22: 411-412.
65. Semaan M, Ivanusic D, Denner J,. Cytotoxic effects during knock out of multiple porcine endogenous retrovirus (PERV) sequences in the pig genome by zinc finger nucleases (ZFN). PLoS ONE 2015; 10: E0122059.
66. Yu JM, Li JS, Ao YY, Duan ZJ,. Detection of novel viruses in porcine fecal samples from China. Virol J 2013; 10: 39.
67. Sachsenröder J, Twardziok S, Hammerl JA, et al., Simultaneous identification of DNA and RNA viruses present in pig faeces using process-controlled deep sequencing. PLoS ONE 2012; 7: E34631.
68. Xiao CT, Giménez-Lirola LG, Jiang YH, et al., Characterization of a novel porcine parvovirus tentatively designated PPV5. PLoS ONE 2013 Jun 7; 8: E65312.
69. WHO, Second WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials October 17-October 17-19 2011, WHO, Geneva, Switzerland. http://www.who.int/transplantation/xeno/en/
70. Tyshenko MG, Bertram L, Li L, et al., Update on the provisional estimation of developing iatrogenic variant Creutzfeldt-Jakob disease from human islet cell transplantation procedures. Transplantation 2014; 97: E73-e75.
71. Yakubovich N, Fung MA, Thompson DM,. Three cases of cytomegalovirus infection following pancreatic islet transplantation. Transplant Proc 2007; 39: 1599-1603.
72. Barshes NR, Agee EE, Zgabay T, et al., West Nile Virus encephalopathy following pancreatic islet transplantation. Am J Transplant 2006; 6: 3037.
73. Mukhopadhyay P, Kumar V, Rathi M, et al., Transmission of human immunodeficiency virus infection by renal transplantation. Indian J Nephrol 2012; 22: 133-135.
74. Waggoner JJ, Soda EA, Deresinski S,. Rare and emerging viral infections in transplant recipients. Clin Infect Dis 2013; 57: 1182-1188.
75. Palacios G, Druce J, Du L, et al., A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008; 358: 991-998.
76. Fishman JA, Greenwald MA, Kuehnert MD,. Enhancing transplant safety: A new era in the microbiologic evaluation of organ donors? Am J Transplant 2007; 7: 2652-2654.
77. Grossi P, Fishman JA,. Guidelines for Transplantation Infectious Disease: Donor-derived infections in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl. 4): S19-S26.
78. Fishman JA, Greenwald MA, Grossi PA,. Transmission of infection with human allografts: Essential Considerations in the Development of Donor Screening Programs. Clin Infect Dis 2012; 55: 720-727.
79. Charrel RN, de Lamballerie X,. Zoonotic aspects of arenavirus infections. Vet Microbiol 2010; 140: 213-220.
80. Fiebig U, Stephan O, Kurth R, et al., Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: Basis for a vaccine for xenotransplantation? Virology 2003; 307: 406-413.
81. Kaulitz D, Fiebig U, Eschricht M, et al., Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs). Virology 2011; 411: 78-86.
82. Waechter A, Denner J,. Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV). Immunol Res 2014; 58: 9-19.
83. Denner J, Mihica D, Kaulitz D, Schmidt CM,. Increased titers of neutralizing antibodies after immunization with both envelope proteins of the porcine endogenous retroviruses (PERVs). Virol J 2012; 9: 260.
84. Waechter A, Eschricht M, Denner J,. Neutralization of porcine endogenous retrovirus by antibodies against the membrane-proximal external region of the transmembrane envelope protein. J Gen Virol 2013; 94 (Pt 3): 643-651.
85. Ramsoondar J, Vaught T, Ball S, et al., Production of transgenic pigs that express porcine endogenous retrovirus small interfering RNAs. Xenotransplantation 2009; 16: 164-180.
86. Dieckhoff B, Petersen B, Kues WA, et al., Knockdown of porcine endogenous retrovirus (PERV) expression by PERV-specific shRNA in transgenic pigs. Xenotransplantation 2008; 15: 36-45.
87. Semaan M, Kaulitz D, Petersen B, et al., Long-term effects of PERV-specific RNA interference in transgenic pigs. Xenotransplantation 2012; 19: 112-121.
88. Charpentier E, Doudna JA, et al., Biotechnology: Rewriting a genome. Nature 2013; 495: 50-51.
89. Cheng JK, Alper HS,. The genome editing toolbox: A spectrum of approaches for targeted modification. Curr Opin Biotechnol 2014; 30C: 87-94.